Specialty pharmaceutical company Cumberland Pharmaceuticals Inc (NASDAQ: CPIX) announced on Monday that it has signed a new contract with Vizient, expanding access to its Vibativ (telavancin) 4-Vial Starter Pak across Vizient's extensive network of US healthcare providers. Vizient serves over 65% of the nation's acute care providers, including 97% of academic medical centres.

The agreement enhances availability of Vibativ's flexible dosing option for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA. Cumberland also offers a 12-vial carton configuration via Vizient distribution channels.

Vibativ, a once-daily injectable lipoglycopeptide antibiotic, has demonstrated efficacy in large-scale studies, outperforming vancomycin in treating HABP/VABP linked to Gram-positive infections, particularly those with vancomycin MIC ≥1 µg/mL. The drug's rapid bactericidal activity and site penetration support its use in complex infection scenarios, including cases complicated by bacteremia.

Based in Tennessee, Cumberland Pharmaceuticals is the state's largest biopharma firm, focused on hospital acute care, gastroenterology and oncology. Its portfolio includes Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol and Vibativ, alongside ongoing Phase II trials for its ifetroban candidate in multiple rare diseases.